Abstract
Cemiplimab is the first treatment approved in patients with aBCC who have progressed on or are intolerant to an HHI based on Study 1620 (NCT03132636), an open-label, multicentre, single arm, non-randomised trial. Prior to cemiplimab availability, there was no standard of care after HHI for advanced BCC patients. The objectives of the current study were to identify and characterise clinical trials and observational studies evaluating the response rates, progression-free survival, or overall survival (OS) of patients with aBCC following HHI receiving systemic therapy or best supportive care (BSC).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
